Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 04, 2015 3:47 AM ET

Commercial Services and Supplies

Company Overview of Cystic Fibrosis Foundation

Company Overview

Cystic Fibrosis Foundation operates as a subsidiary of Walgreens Specialty Pharmacy, LLC.

6931 Arlington Road

2nd floor

Bethesda, MD 20814

United States

Founded in 1955





Key Executives for Cystic Fibrosis Foundation

Chief Executive Officer and President
Age: 71
National Director of Special Projects
Compensation as of Fiscal Year 2015.

Cystic Fibrosis Foundation Key Developments

Cystic Fibrosis Foundation Announces Executive Changes, Effective December 31, 2015

Cystic Fibrosis Foundation announced that Robert J. Beall, Ph.D., will step down as president and chief executive officer, effective December 31, 2015. He will be succeeded by Preston W. Campbell III, M.D., currently the foundation's executive vice president for medical affairs, a position he has held since 1998. Beall and Campbell will work closely together to provide for a seamless transition of leadership and ensure the foundation's strong momentum continues.

Cystic Fibrosis Foundation Announces FDA Approval of Orkambi as Important Advance for the Cystic Fibrosis Community

The Cystic Fibrosis Foundation announced the FDA’s approval of the lumacaftor/ivacaftor combination drug (Orkambi™) as an important advance for the cystic fibrosis community. Orkambi targets the underlying cause of the disease in people with two copies of the most common CF gene mutation, F508del. The FDA approved the drug for people with CF ages 12 and older who have two copies of the F508del mutation, representing 8,500 people or nearly one-third of the CF population in the United States. Nearly half of individuals with CF have two copies of this mutation and could eventually benefit from the therapy. Orkambi was developed by Vertex Pharmaceuticals Inc. with significant clinical, scientific and funding support from the CF Foundation.

Cystic Fibrosis Foundation Presents at CED Life Science Conference 2015, Mar-03-2015 02:15 PM

Cystic Fibrosis Foundation Presents at CED Life Science Conference 2015, Mar-03-2015 02:15 PM. Venue: Raleigh Convention Center, Raleigh, North Carolina, United States. Speakers: Robert J. Beall, Chief Executive Officer and President.

Similar Private Companies By Industry

Company Name Region
Veolia ES Waste-to-Energy, Inc. United States
Airex Transportation Services United States
Modular Furniture Group, Inc. United States
Kansas Blue Print, Inc. United States
Lisa Frank, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Cystic Fibrosis Foundation, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at